Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Israel - English - Ministry of Health

abic marketing ltd, israel - bortezomib - powder for solution for injection - bortezomib 1 mg - bortezomib - bortezomib teva is indicated for the treatment of patients with multiple myeloma. bortezomib teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation

Israel - English - Ministry of Health

abic marketing ltd, israel - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezo teva is indicated for the treatment of patients with multiple myeloma. bortezo teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezo teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Israel - English - Ministry of Health

inovamed ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib inovamed is indicated for the treatment of patients with multiple myeloma.bortezomib inovamed is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib inovamed in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - bortezomib as mannitol boronic ester - powder for solution for injection - bortezomib as mannitol boronic ester 3.5 mg - bortezomib - multiple myelomabortezomib s.k is indicated for the treatment of patients with multiple myeloma.mantle cell lymphomabortezomib s.k is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.bortezomib s.k in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Israel - English - Ministry of Health

abic marketing ltd, israel - bortezomib - powder for solution for injection - bortezomib 2.5 mg - bortezomib - bortezomib teva is indicated for the treatment of patients with multiple myeloma. bortezomib teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation

Israel - English - Ministry of Health

teva israel ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib teva is indicated for the treatment of patients with multiple myeloma. bortezomib teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation

Israel - English - Ministry of Health

taro international ltd, israel - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - bortezomib is indicated for the treatment of patients with multiple myeloma.bortezomib is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Israel - English - Ministry of Health

j-c health care ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma.velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag, belgium - bortezomib - powder for solution for injection - 3.5 mg